Biocept, Inc. (BIOCQ)

Biocept Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Jun 30, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Net Income	-30.61	-32.09	-2.82	-17.81	-25.14	-24.57
Depreciation & Amortization	1.83	1.66	1.53	1.09	0.93	0.8
Loss (Gain) From Sale of Assets	0.05	0.01	0	-0	-	-
Stock-Based Compensation	1.41	3.23	2.46	0.94	0.87	0.62
Other Operating Activities	-1.41	0.62	1.11	2.26	1.69	-0.01
Change in Accounts Receivable	11.78	11.64	0.36	-10.62	-1.95	-0.38
Change in Inventory	1.7	1.89	-0.72	-1.41	-0.19	-0.05
Change in Accounts Payable	-2.7	-5.86	-0.41	4.47	0.01	0.6
Change in Other Net Operating Assets	0.36	5.62	2.19	1.29	0.73	0.63
Operating Cash Flow	-17.6	-13.29	3.69	-19.79	-23.05	-22.36
Capital Expenditures	-0.68	-0.81	-1.57	-0.87	-0.74	-0.15
Sale of Property, Plant & Equipment	0.08	-	-	-	-	-
Investing Cash Flow	-0.61	-0.81	-1.57	-0.87	-0.74	-0.15
Long-Term Debt Repaid	-	-2.11	-1.77	-1.54	-0.93	-1.92
Net Debt Issued (Repaid)	-2.19	-2.11	-1.77	-1.54	-0.93	-1.92
Issuance of Common Stock	4.1	0.24	14.15	27.26	30.6	25.69
Financing Cash Flow	1.91	-1.87	12.38	25.72	29.66	23.78
Net Cash Flow	-16.3	-15.97	14.5	5.07	5.88	1.28
Free Cash Flow	-18.28	-14.1	2.12	-20.65	-23.78	-22.5
Free Cash Flow Margin	-1346.87%	-54.51%	3.46%	-75.21%	-430.21%	-692.26%
Free Cash Flow Per Share	-26.47	-24.94	4.30	-52.31	-345.36	-
Cash Interest Paid	0.2	0.32	0.29	0.24	0.25	0.61
Cash Income Tax Paid	-	-	-	-	-	0
Levered Free Cash Flow	-4.24	-9.22	0.86	-14.75	-15.48	-13.61
Unlevered Free Cash Flow	-4.11	-9.02	1.05	-14.6	-15.32	-13.42
Change in Working Capital	11.14	13.29	1.41	-6.27	-1.4	0.8

Updated Aug 14, 2023. Source: S&P Global Market Intelligence. Standard template. Financial Sources.